A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD2
- Sponsors Eli Lilly; Eli Lilly Japan
- 01 Oct 2018 Planned End Date changed from 18 Jan 2019 to 9 Jan 2019.
- 01 Oct 2018 Planned primary completion date changed from 21 Dec 2018 to 12 Dec 2018.
- 20 Aug 2018 Status changed from recruiting to active, no longer recruiting.